Skip to content

Survodutide: Benefits & Research

Part of the Survodutide Complete Guide

Partner

Research Peptides

BioLongevity Labs15% Off
Shop Peptides at BioLongevity Labs

We may earn a commission if you purchase through this link, at no extra cost to you.

Weight Loss

Phase 2 trials demonstrated up to 18.7% body weight loss — comparable to or exceeding semaglutide. The dual GLP-1/glucagon mechanism provides weight loss through appetite suppression (GLP-1) and increased energy expenditure (glucagon).

MASH Improvement

The Phase 2 MASH trial published in NEJM showed survodutide significantly improved liver histology — achieving MASH resolution without worsening fibrosis in up to 83% of patients at the highest dose. The glucagon component drives hepatic lipid oxidation, directly addressing the liver fat accumulation underlying MASH.

Metabolic Benefits

Survodutide improved multiple metabolic parameters including HbA1c, liver enzymes (ALT), triglycerides, and waist circumference. The dual mechanism addresses both systemic (obesity) and organ-specific (liver) metabolic dysfunction.

Frequently Asked Questions

References

  1. Sanyal AJ, et al.. Survodutide for the treatment of MASH: a randomized phase 2 trial. NEJM, 2024.

Researching peptides? We did the hard part.

Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.

Related Guides

PI

Peptides Insider Editorial Team

Our content is reviewed for accuracy and grounded in peer-reviewed research where available. We do not provide medical advice. Always consult a qualified healthcare professional.